- Home
- GALT vs IDYA Comparison
GALT vs IDYA Comparison
Compare GALT & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- IDYA
- Stock Information
- Founded
- GALT 2000
- IDYA 2015
- Country
- GALT United States
- IDYA United States
- Employees
- GALT N/A
- IDYA 124
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- GALT Health Care
- IDYA Health Care
- Exchange
- GALT Nasdaq
- IDYA Nasdaq
- Market Cap
- GALT N/A
- IDYA 2.5B
- IPO Year
- GALT N/A
- IDYA 2019
- Fundamental
- Price
- GALT $2.63
- IDYA $29.48
- Analyst Decision
- GALT Strong Buy
- IDYA Strong Buy
- Analyst Count
- GALT 1
- IDYA 10
- Target Price
- GALT $11.00
- IDYA $56.00
- AVG Volume (30 Days)
- GALT 140.6K
- IDYA 938.0K
- Earning Date
- GALT 11-11-2024
- IDYA 11-05-2024
- Dividend Yield
- GALT N/A
- IDYA N/A
- EPS Growth
- GALT N/A
- IDYA N/A
- EPS
- GALT N/A
- IDYA N/A
- Revenue
- GALT N/A
- IDYA $11,961,000.00
- Revenue This Year
- GALT N/A
- IDYA N/A
- Revenue Next Year
- GALT N/A
- IDYA $94.96
- P/E Ratio
- GALT N/A
- IDYA N/A
- Revenue Growth
- GALT N/A
- IDYA N/A
- 52 Week Low
- GALT $1.56
- IDYA $23.41
- 52 Week High
- GALT $4.27
- IDYA $47.74
- Technical
- Relative Strength Index (RSI)
- GALT 48.38
- IDYA 35.83
- Support Level
- GALT $2.67
- IDYA $29.05
- Resistance Level
- GALT $3.16
- IDYA $31.54
- Average True Range (ATR)
- GALT 0.16
- IDYA 1.78
- MACD
- GALT -0.02
- IDYA -0.07
- Stochastic Oscillator
- GALT 13.11
- IDYA 5.67
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.